Financial Disclosure

Speaker, Martin Pearlman, M.D. has a financial interest/agreement or affiliation with Lansing Ophthalmology, where he is employed as a retina specialist.

Case VC History

53 y/o physician with a 1 day history of loss of vision OS.

Past ocular history:

traumatic uveitis OD as a child

Lattice retinal degeneration OD

Pseudophakia OD

Past Medical history:

osteoarthritis

elevated cholesterol

benign prostatic hypertrophy

Case VC exam

OD OS

V.A. 20/20 20/30

IOP 14 20

Color vision intact intact

Amsler Grid WNL metamorphopsia

SL PCIOL trace cat


tr flare, no cells No cells, flare

Periph fundus LRD LRD


Macula No def ME +/-ME















Case VC OD 6-23-10 (332u)

DOB:

5/20/1947

High Definition Images: HD 5 Line Raster OD ● ○ OS



Doctor's Signature


SW Ver. 6.0.1.24 Copyright 2012 Carl Zeiss Meditec, Inc. All Rights Reserved Page 1 of 1


Comments

Bertal Number: 4000-3399 Gender Male Doctor: Signal Strength: 9/10 OD O OS High Definition Images: HD 5 Line Raster Scan Angle: 90" Spacing: 0.25 mm Length: 6 mm Comments Doctor's Signature SW Ver: 6.0.1.24 Copyright 2012 Carl Zelss Meditor, Inc. All Rights Reserved Page 1 of 1

Lansing Ophthalmology

Case VC OS 6-23-10 (447 u)





Page 1 of 1

• Diagnosis: ??

• Treatment: ??

- Pseudophakic Cystoid Macular Edema
- Docataxel Retinopathy
- Paclitaxel Retinopathy
- Nicotinic Acid Maculopathy
- Idiopathic Non-staining CME


Case VC Missing Information


- This physician treated his elevated cholesterol for 3 months prior to being seen with 3 gm. Per day of niacin.
- When he developed blurred vision he stopped the niacin one day prior to being seen.

Case VC 1 Month Later

- Metamorphopsia resolved
- Vision 20/20 OU
- Edema resolved.

Case VC 1 Month Later (266u)






Copyright 2012 Carl Zeiss Meditec, Inc.

Page 1 of 1

All Rights Reserved

Case VC OS 1 Month Later (239u)



30026007 ID: Exam Date: Lansing Ophthalmology DOE 5/20/1947 Exam Time: Gender: 4000-3399 Male Sartal Number: Signal Strength: 10/10 OD O OS High Definition Images: HD 5 Line Raster Scan Angle: 90° Spacing: 0.25 mm Length: 6 mm

Doctor's Signature

Comments Doctor's Signature

SW Ver. 6.0.1.24 Copyright 2012 Carl Zeiss Meditec, Inc. Comments

SW Ver. 6.0.1.24 Copyright 2012 Cart Zeiss Mediter, inc All Rights Reserved Page 1 of 1

Nicotinic Acid Maculopathy

- Described by Gass in 1973
- Affects <1% of patients taking niacin for hyperlipidemia
- Occurs with higher doses of niacin (>3gm./day)
- Resolves when niacin is withdrawn.
- Consists of CME without vitritis or retinal vascular changes.
- No dye leakage on fluorescein angiography.
- Cystic spaces in the outer nuclear layer & inner plexiform layer on OCT.

Nicotinic Acid Maculopathy

- Cause unknown
- Speculate capillary permeability is too little to allow fluorescein to escape.
- Speculate Muller cell abnormality

References

- Gass JDM. Nicotinic Acid Maculopathy. Am J Ophthalmol 1973;76:500-10
- Millay RH,Illingworth DR. Niacin Maculopathy 1988;95:930-6
- Spirn MJ, Warren FA, Guyer DR, Klancnik JM, Spaide RF Optical Coherence Tomography Findings in Nicotinic Acid Maculopathy. Am J Ophthalmol 2003; 135:913-4
- Dajani HM, Lauer AK. Optical Coherence Findings in Niacin Maculopathy Canad J Ophthalmol 2006;41:197-200
- Jampol LM Niacin Maculopathy. Ophthalmology 1988;95:1704-5